<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="152893">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01721590</url>
  </required_header>
  <id_info>
    <org_study_id>SYNH-20120929</org_study_id>
    <nct_id>NCT01721590</nct_id>
  </id_info>
  <brief_title>Tongxinluo Improve High on Clopidogrel Platelet Reactivityn Patients With Coronary Heart Disease</brief_title>
  <acronym>Talent</acronym>
  <official_title>Study of Tongxinluo to Improve High on Clopidogrel Platelet Reactivity in Patients With Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yaling Han</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenyang Northern Hospital</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tongxinluo is a kind of Chinese patent drug,which could promote blood circulation.Recent
      reports suggested that tongxinluo's effectiveness in reducing the thrombin activity.In this
      prospective randomized study,all patients in control group will receive blank placebo ,all
      patients in test group will receive tongxinluo.All patients will be followed up for one
      year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint is Platelet aggregation rate( by VerifyNow) at 30 days.The secondary
      endpoints include inflammation marker (hsCRP、CD62P-CD41),BT、FIB and APTT at 30 days,and
      MI、Ischemic Stroke and all-cause mortality 、bleeding events at 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Platelet aggregation rate( by VerifyNow)</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammation Marker (hsCRP、CD62P-CD41)</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BT、FIB and APTT</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Ischemia event</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Including MI、Ischemic Stroke and all-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding event</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reaction and withdrawal rate</measure>
    <time_frame>1 month ，1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina recurrence</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Traditional Chinese medicine angina symptoms scores</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-stent thrombosis</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Conrol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo，3 capsules/time，3times/day for 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tongxinluo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tongxinluo 3 capsules/time 3times/day for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tongxinluo</intervention_name>
    <description>Tongxinluo</description>
    <arm_group_label>Tongxinluo</arm_group_label>
    <other_name>Tongxinluo capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - (1)ACS (including unstable angina pectoris, non-ST-segment elevation myocardial
        infarction and ST-elevation myocardial infarction) （2）Accept at least one coronary stent.
        （3）The age between18 and 75 . （4）High on-treatment platelet reactivity defined as an
        ADP-induced platelet aggregation (by VerifyNow，PRU≥236）at 24 hr after clopidogrel loading
        (300 ~ 600mg)or 24 hours after PCI.

        （5）Informed Consent

        Exclusion Criteria:

          -  （1）Tongxinluo contraindication . （2）Receiving GP IIb / IIIa receptor antagonist
             treatment （3）Who complicate the known bleeding tendency and blood system diseases.
             （4）NYHA grade III ~ IV （5）Aspirin or clopidogrel allergies （6）Severe liver or kidney
             dysfunction （7）Pregnancy （8）Cann't accept 30 days supervision and blood proofer.
             （9）Other serious illness, life expectancy less than 6 months. （10) Planned surgery
             recently （11) PCI again within 30 days. (12) Mental diseases interfering
             understanding the informed consent form （13）Accept other drugs or participate in
             other clinical research at the same time .
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaling Han, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenyang Northern Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yaling Han, MD</last_name>
    <phone>+86-24-23922184</phone>
    <email>13998847715@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ShenZhou Hopital Of ShenYang Medical College</name>
      <address>
        <city>ShengYang</city>
        <state>Liaoning</state>
        <zip>110032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lu Li, MD</last_name>
      <phone>13309882525</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yaling Han, Dr</last_name>
      <phone>+86-24-23922184</phone>
      <email>13998847715@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yaling Han, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lei Zhang, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meiling Ge, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The 463th Hospital Of PLA</name>
      <address>
        <city>ShenYang</city>
        <state>Liaoning</state>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongyun Zang, MD</last_name>
      <phone>15309885517</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 1, 2012</lastchanged_date>
  <firstreceived_date>November 1, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shenyang Northern Hospital</investigator_affiliation>
    <investigator_full_name>Yaling Han</investigator_full_name>
    <investigator_title>vice president</investigator_title>
  </responsible_party>
  <keyword>high on-treatment platelet reactivity</keyword>
  <keyword>Coronary Heart Disease</keyword>
  <keyword>Tongxinluo</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
